Ousted Biolase CEO Federico Pignatelli launches an investigation into the device maker, saying he suspects “wrongdoing, mismanagement and corporate governance failures.”
Shares of Biolase (NSDQ:BIOL) got a modest boost today, even as a company insider announced a far-reaching investigation into the company’s management under the suspicion of wrongdoing.
Former CEO Federico Pignatelli, ousted earlier this month by a court order spurred by activist investor Oracle Partners, issued a statement today accusing members of Biolase’s board of “possible company mismanagement.”
Help employers find you! Check out all the jobs and post your resume.
